Introduction
Pancreatic cancer is the 4 th most aggressive cancer in the western world [1] . Unfortunately, no major advancement in patient diagnosis, treatment or prognosis has been made in the last 40
years. Thus the number of deaths from this disease is set to rise approximately 28% by 2026 [2] . Treatment of this disease is often hindered by lack of symptoms, late diagnosis and the lag time between diagnosis, referral and treatment. Of those patients diagnosed with pancreatic cancer approximately 80% will die within a year of diagnosis and only 3% will survive 5 years [2] . In order to treat this devastating disease new technologies which overcome the major barriers to treatment must be developed. Currently the first line chemotherapy for pancreatic cancer is nucleoside analogue, gemcitabine. However, gemcitabine only proves effective in 23.8 % of patients [3] . It is thought this is due to a dense stroma which surrounds the tumours and hampers drug penetration [4] . One strategy that has shown promise to increase drug penetration and increase efficiency of treatments is to couple chemotherapies onto nanoparticle carriers [5] [6] [7] [8] [9] [10] . Nanoparticulates possess the ability to be either passively targeted to tumour vasculature through the enhanced permeability and retention effect [11] or actively targeted to specific sites after functionalisation with specific ligands [12] . Previous studies have shown that after coupling cytotoxics onto nanoparticles, this increased tumour penetration and resulted in more effective therapies [13] [14] [15] [16] .
Iron oxide-gold hybrid nanoparticles (HNPs) have recently been the focus of a number of investigations and are becoming increasingly applicable in biomedicine [17] [18] [19] [20] . By using iron oxide (Fe 3 O 4 ) and elemental gold (Au) within one platform, a multifunctional and stable system can be fabricated [21, 22] . This exploits the surface chemistry and heating potential resulting from laser irradiation at the surface plasmon resonance (SPR) of the gold coating and the magnetic character of the iron oxide core, offering potential as an image guided drug carrier or theranostic agent. Reports using HNPs for delivery of anticancer agents have attached chemotherapies onto the gold surface via linker moieties or exploitation of sulfurgold chemistry [22, 23] .
In this study drug attachment onto the gold surface of HNPs via electrostatic interaction is explored for the first time as a potential loading and release strategy. Electrostatic interactions with polymers or stabilising agents are commonly used for functionalisation of nanoparticles but, to the best of our knowledge, have not been reported as a mechanism for stimuli responsive drug delivery from HNPs. Stimuli responsive drug delivery occurs when drug release is initiated by a change in environmental conditions, such as temperature or pH. The rationale is that positively charged drug molecules will form electrostatic interactions with the overall negatively charged gold surface of the HNPs. Electrostatic bonds are chargecharge interactions which may be cleaved at increased temperatures when the energy threshold required to break these bonds is reached [24] . Here we exploit the nano-heating properties of these HNPs in order to break the electrostatic binding of drug molecules which results in localised triggered drug release (Fig. 1A) . This reversible binding mechanism allows for controllable release of pharmaceutical agents in their parent state unhindered by addition of linkers or permanent bonds, hence no reduction in drug activity is experienced as is so commonly observed in controlled release systems [25] .
Here a series of novel bisnaphthalimide drug analogues with a chain of 20 atoms separating two naphthalimido residues will be used (Fig. 1B) . Brana et al. reported bisnaphthalimides as potent chemotherapeutic agents [26] [27] [28] [29] . Bisnaphthalimide derivatives are identified to possess significant anti-tumour activity in both murine and human cancerous cells [26] [27] [28] [29] .
Due to the presence of planar aromatic moieties, these molecules can intercalate within the DNA by entry via the major groove [30] . Hoskins et al. showed that the potency of an insoluble bisnaphthalimido compound could be enhanced in vitro and in vivo in pancreatic models using a nano-aggregate of poly(allylamine) modified with cholesteryl chains. This aggregate increased drug solubilisation and resulted in more rapid drug uptake into pancreatic cancer BxPC-3 cells compared with the free drug. A similar clinical effect was experienced with the clinically used drug gemcitabine at 8-fold less dose [31] .
In this study, a number of soluble bisnaphthalamide analogues with a backbone containing different number of charged amino residues were electrostatically conjugated onto the HNP surface (Fig. 1A) . In order to determine the effect of drug charge on the loading concentration and subsequent drug release, we used bisnaphthalimido: 1,20 diaminoicosane (BNIPDi) (containing no amino residues), 1,12 diaminooctane dihydrogen bromide (BNIPd), propyl spermine tetrahydropbromide (BNIPSpm), and propyl 3,3'-butane-1,4-diylbis(sulfanediyl)bis(propan-1-amine) (BNIPds) (Fig. 1B) . The temperature dependant release and biological activity of the novel systems was evaluated both in vitro and in vivo in order to ascertain clinical relevance of these systems for pancreatic cancer therapy.
Experimental
All chemicals and solvents used were commercially available and purchased from Sigma Aldrich (UK) unless otherwise stated. Anhydrous solvents were purchased as such or dried using standard techniques. Cell culture media was purchased from Thermofisher (UK). All cell lines used were purchased from ATCC, LGC Standards UK and mice were purchased from Charles River, UK.
Synthesis and characterisation of drug molecules
The drug compounds were synthesised according to the methodology outlines in the Supplementary Information (SI-Methods 1.0). The drugs were characterised using 1 H, 13 C and 19 F NMR spectra which were recorded at 300 MHz using a Bruker Spectrospin DPX 300
Spectrometer and at 400 MHz using a Bruker Ascend 400 spectrometers; Multiplicities were recorded as broad peaks (br), singlets (s), doublets (d), triplets (t), quartets (q), quintets (qu), double doublets (dd), and multiplets (m). All NMR samples were made up in deuterated solvents with all values quoted in ppm relative to tetramethylsilane (TMS) as an internal reference. Coupling constants (J values) are reported in Hertz (Hz). High resolution mass spectrometry analyses were performed using a ThermoFisher Scientific LTQ Orbitrap XL hybrid ion trap-orbitrap mass spectrometer. Samples were introduced to the spectrometer as solutions in dichloromethane/methanol with ammonium acetate added. All compounds analysed gave satisfactory data at high resolution as compared to predicted ionisation patterns. Formulations with the highest drug loading concentrations (5 mL) were freeze dried using a
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Heto PowerDry LL3000, Thermo-Fisher UK. The freeze dried samples were analysed by FTIR spectroscopy using a diamond tipped attenuated total reflectance attachment (Nicolette iS5 with iD5 ATR, Thermo-Fisher UK) at resolution of 4 cm -1 and 64 scans were run at room temperature with background subtraction in order to qualitatively verify drug presence.
Aqueous formulations were characterised at room temperature on the Luminescence Spectrometer (Varian, Cary Eclipse Fluorescence Spectrophotometer, USA) with excitation wavelength set at 234 nm. The samples were scanned for emission between 200 -600 nm at 400 nmsec -1 , and the spectra were collected and analysed by the provided software. This software controls all aspects of the system, such as control of the slits at the entrance and exit ports of the spectrograph, detector gain, blank-subtraction, system correction files and automated batch-processing.
Zeta potential measurements were carried out using a photon correlation spectrometer (PCS, Zetasizer Nano-ZS, Malvern Instruments, UK). Samples were diluted in deionised water to make 1 mgmL -1 of HNPs and sonicated for 30 s before measuring the surface charge of the particles at 25 °C.
Photon correlation spectroscopy (PCS) carried out in order to evaluate particle size before and after drug conjugation. Samples were analysed at 25 °C using a PCS, Zetasizer Nano-ZS, Malvern Instruments, UK). Samples were run in triplicate and an average value recorded.
Additional size measurements were carried out using transmission electron microscopy (TEM). TEM imaging was carried out using the JEOL JEM-1230 (JEOL, Japan) transmission electron microscope. Prior to imaging, formvar coated copper grids were prepared. The samples were pipetted (10 µL) onto the grids and allowed to air dry before imaging. Sample diameter was measured and recorded for 20 particles and an average size recorded.
Stability of HNP-drug formulations
The formulations were tested as both aqueous solutions and dried formulations. These studies was run at both room temperature and 4 ˚C over the period of 4 weeks. For the aqueous formulations, 1 mL of each formulation (drug concentration = 0.5 mgmL -1 ) was kept at room temperature and 4 ˚C and the supernatant was analysed each week with HPLC. For studying the stability of powder formulations 1 mL of each formulation with the same mentioned concentration was freeze dried. Each week samples were reconstituted in deionised water and the concentration of released drug investigated via HPLC as previously described. All measurements were run in triplicate and recorded as average values.
In vitro drug release
Formulations (2 mL, 500 µgmL (1 mL) was removed and replaced with 1 mL deionised water at the specified time points. All samples were diluted with 1 mL of acetonitrile and drug concentrations were analysed via HPLC as previously described. The experiment was carried out in triplicate and the peak area compared to a calibration of the free drug dissolved in acetonitrile/H 2 O (50:50) (R 2 = 0.999).
In vitro evaluation
Human pancreatic adenocarcinoma (BxPC-3), human epithelial ductal carcinoma (PANC-1) and human myeloid monocyte (U937) cells were cultured in RPMI (BxPC-3 & U937) AND DMEM (Panc-1) media. The media was supplemented with 1 % penicillin/streptomycin and 10 % foetal bovine serum (1 % of L-glutamine was also added to PANC-1 & U937 media).
U937 cells were differentiated with 0.02 % of phorbol-12-myristate 13-acetate (PMA) (50 µgmL -1 in PBS) was added to the cells suspension in order to transform them into macrophage like cells before testing.
MTT Assay
Cells (100 µL, 15000 cells/well) in exponential growth phase were seeded into 96 well flat bottomed plates and incubated for 24 h at 37 °C with 5 % CO 2 . After 24 h, the media was 
Trypan blue cytotoxicity test
Cells ( 
Cellular uptake of formulations
Cells (3 mL, 150000 cells/ well) were seeded into 6-well plates and incubated for 24 h at 37°C with 5 % CO 2 . The media was replaced with 50 µgmL -1 and 100 µgmL -1 of different bisnaphthalamide based drugs, their hybrid formulations and gemcitabine and incubated for 1 h and 4 h. The medium was removed and each well was washed with 1 mL PBS before the addition of 185 µL trypsin into each well. Cells re-suspended in 1 mL media and viable cells were counted using an automated cell counter (Invitrogen Countess Ò , UK). Cells (100,000)
were transferred into eppendorf tubes and centrifuged (800 rpm, 5 min). The supernatant was removed and cells were resuspended in DMSO:water (1:1) (for samples containing bisnaphthalamide derivatives) or water (for samples containing gemcitabine). The drug concentration was quantified using reverse phase HPLC. Analysis of the bisnaphthalimides was carried out via HPLC as described in the drug loading methodology. Gemcitabine quantification was carried out using an HPLC instrument with UV detector (Perkin Elmer, Flexar Autosampler, column: SPHERISORB ODS 2 5µm, length 250 mm, internal diameter 4.6 mm) and a mobile phase of water:acetonitrile (30:70). The samples were detected at 234 nm with flow rate of 1 mL.
Thermo-responsive cytotoxicity
Cells (3 mL, 150000 cells/well) in their exponential growth phase were seeded into 6-well plates and incubated for 24 h at 37 °C with 5 % CO 2 . Cells were treated with 50 µgmL -1 of drugs and formulations and incubated for 1 h. Then, cells were further incubated at 25 °C, 44
VC and 60 °C for 0.5 h, in order to investigate the effect of temperature on cell cytotoxicity.
Then the drug solutions were removed and cells were washed with fresh media to remove any excess drug. Fresh media was then added to each well. After 24 h incubation (37 °C, 5 % CO 2 ), media was removed and cells were washed with PBS. The cells were counted using trypan blue exclusion as described above.
AFM topography imaging
Cells (3 mL, 150000 cells/well) were seeded in 6-well plates containing glass coverslips and 
In vivo evaluation
Female Nu/Nu mice, 5 weeks of age (Charles River, UK) were kept in pathogen-free 
2.7Statistical analysis
A simple two tailed t-test was carried out in excel to determine the statistical significance of results, whereby p£0.01 was significant.
Results and Discussion

Synthesis and characterisation of drug molecules
The drug molecules used in this study were synthesized using established methodology according to the general scheme shown in Fig. 2 [33] . The identity of these compounds was confirmed by NMR spectroscopy and Mass spectrometry (SI- Fig. 1 ).
HNP-Drug conjugation and characterisation
The HNP preparation and characterisation has been reported previously [21, 22] along with their ability to undergo triggered heating upon laser irradiation in agar phantoms [17, 34] , in vitro and in situ in tumour bearing mouse cadavers [35, 36] . Drug attachment was carried out at three drug:HNP weight ratios (5:1, 2.5:1 and 1:1 based on Fe weight of HNP) for all four bisnaphthalamide based drugs. Higher initial drug weight concentrations were not investigated due to the lack of aqueous solubility of the drug analogues over 5 mgmL -1 . The data suggested that BNIPDi could not be conjugated onto the surface of HNPs due to the lack of protonated amino group (Fig. 3A) , which is essential for electrostatic interaction, or any other driving force for conjugation. FTIR spectral analysis (SI- Fig.2A ), fluorescence spectroscopy (SI- Fig.3A ) and the lack of shift in zeta potential measurement of the BNIPDi formulations ( Fig. 3B) confirmed that no drug attachment had occurred. As a result, it was decided not to study these formulations further. Photon correlation spectroscopy (SI- Table 1) was inconclusive in terms of nanoparticle size. This was due to the fact that aggregation was occurring on measurement, particularly in the HNP with no drug coating. Indeed the measurements appeared to become more realistic after drug conjugation , this is likely to be due to the stabilizing effect of the drug on the HNPs in solution, hence reducing their tendency to aggregate in solution. Size measured via TEM showed that there was no notable increase in particle size after drug conjugation onto the surface of the HNPs.
Drugs with amino groups within their backbone did successful achieve binding onto the gold surface ( (Fig. 3A) suggesting weak electrostatic interactions being formed and broken due to competition of drug molecules for space on the HNP surface with surface saturation not being achieved.
For BNIPSpm, increasing drug loading concentration resulted in greater drug attachment onto the nanoparticle surface (Fig. 3A) . This could be due to the number of protonated amino groups present in the drug backbone (four in the case of BNIPSpm when compared to two in Previous studies have shown that doxorubicin can be absorbed onto colloidal gold surfaces and electrostatically attached. In the case of this drugs, it has been shown that the hydrophobic moieties within the structure drive the molecule towards the gold surface and secondly the charge within the compound resulting from the one primary amine allow for electrostatic attachment [39] . The mechanism of bisnaphtalamide drug attachment onto the HNP surface may undergo a similar mechanistic approach to attachment, however, the multiple amine charges resulting from the polyamine chain far outweigh the hydrophobicity of the naphthalamide moieties within the drug structure resulting in a freely soluble drug compound, unlike in the case of doxorubicin. Hence, the mechanism in this case may solely rely on charge-charge interaction, without the initial push from the hydrophobic aromatic groups. More work is required in order to confirm the exact mechanism of the electrostatic interactions obtained for these drugs.
Stability of HNP-drug formulations
Stability studies of the drug-HNP formulations (Fig. 3C&D) , including reconstituted freezedried samples, were carried out in aqueous solution at 4 ˚C and room temperature (25 ˚C).
These results showed that BNIPds did not dissociate from the HNP surface, which was expected due to the covalent linkage between sulfide and the Au surface of the HNP. BNIPd became almost totally unattached from the HNPs at both 4 ˚C and 20 ˚C probably due to the weak electrostatic interaction being broken down. BNIPSpm however, remained in formulation with more than 80 % of drug remaining attached to the HNPs in solution over the duration of the study. This is probably due to the increased number of charges in the drug resulting in a greater electrostatic force and tighter binding. The freeze-dried formulations were optimal with increased longevity observed.
In vitro drug release
Drug release was carried out under 'sink' conditions in aqueous solution (Fig. 4A ) and in cell culture media with pH adjusted to mimic in vivo conditions (Fig. 4B) . Studies with BNIPd showed that 100 % of the drug was released rapidly at 20 ˚C (almost 80 % after 0.5 h) (SI Fig.4) ; it is proposed that the charge-charge interaction is not strong enough for long-term stability of the formulation. Such instability and rapid dissociation from the formulation renders it unsuitable as a delivery system for this drug. In general, the BNIPSpm release from formulations in both water and culture media showed biphasic patterns, which include a sharp release in the first 10 h followed by a gradual release for the remainder of the experiment.
Less than 10 % of drug had been released at a biologically relevant temperature i.e. 37 o C. At 60 ˚C higher drug release occurred, after only 0.5 h almost 40 % of drug had been released from the formulations, which may also be achievable upon irradiation of the HNPs at the SPR over short time durations without detriment to surrounding cells. The release profiles of
BNIPSpm formulations indicate that they are superior to the BNIPd formulations. It is hypothesized that the increased number of charged residues in BNIPSpm results in stronger electrostatic interactions which requires a larger input of energy to dissociate it from the HNP surface, thus the formulation is more stable at lower temperatures and only releases drug after heat stimulation.
In our study BNIPSpm drug release in culture media at biologically relevant temperatures (37 ˚C) and pH (7.4) followed the same pattern of drug release seen in water, whereby increasing the temperature (from 37 ˚C to 44 ˚C) enhanced the drug release rate. A decrease in pH to intracellular levels resulted in further drug release. At pH 3.6, there was a significant increase in drug released from BNIPSpm-HNP compared to physiological pH. Thus, BNIPSpm-HNP formulations exhibited pH and thermo-responsive drug delivery properties. Therefore, it is envisaged that after accumulation of the HNPs inside the endosomes or lysosomes together with the low environmental pH accompanied by heating through laser irradiation will result in rapid drug release from the nanoparticles. Thus, allowing free drug to enter the nucleus to interact with DNA for therapeutic effect. As expected, due to the robust binding interaction of BNIPds, less than 2 % of the drug was released after 72 h at 60 ˚C (SI- Fig.4) . Therefore, BNIPds formulations cannot be utilised for thermally triggered drug delivery.
Based on the above results, only BNIPSpm formulation studies were carried forward for in vitro and in vivo testing on pancreatic cancer cells.
In vitro evaluation
Cell viability of BxPC-3, Panc-1 and U937 cells exposed to HNP-BNIPSpm was determined using both the MTT assay and trypan blue exclusion (Fig. 5A ). BxPC-3
and Panc-1 cell lines were chosen in this study in order to gain realistic information on the potential of the formulations in pancreatic therapy. Cancer is not defined as one cell type, indeed it is a cellular mutation which leads to rapid proliferation, this can occur in multiple cell types within one cancer, which may react differently to treatment. Therefore, looking at more than one cell line may give more meaningful information and correlation between cellular response and in vivo outcome. In this study, generally, both cytotoxicity assays exhibited comparable results in the pancreatic cell lines. The naked HNPs did not present a remarkable dose response effect on cell viability up to 50 µgmL -1 (p>0.05) (SI- Fig.5 ). However, after 24 h incubation with the highest concentration of HNPs (100 µgmL -1 ) a 19-23% decrease in viability was obtained (p<0.05). As with any drug delivery vehicle, inherent toxicity is not desirable. In this case it is not a concern since the concentrations tested are more potent than would be expected to be administered in the drug formulation to a patient in the clinic. Over the concentration ranges and time points tested there was no IC 50 evident for either the HNP (SI- Fig.4A ) or gemcitabine (SI- Fig.4B ). As gemcitabine is the gold standard for clinical treatment it was interesting to note that for BNIPSpm, after only 24 h an IC 50 value was detected, hence this indicates that the novel drug is more rapid and potentially more toxic than the clinical gold standard.
Consistently in the pancreatic cancer cell lines (BxPC-3 and Panc-1), when BNIPSpm was conjugated onto the HNP a decrease in IC 50 was achieved. This was particularly evident in the case of BxPC-3 cells where a significant (p<0.01) reduction in IC 50
values was observed in both the MTT and trypan blue exclusion assays with an IC 50 as low as 1.37 µgmL -1 in BxPC-3 cells (Fig. 5A) . The increase in activity may be due to the internalisation mechanism of the drug. It is hypothesized that the free drug is internalised into the cell via a diffusion driven pathway which is time consuming.
When studying the data of gemcitabine cellular uptake (SI- Fig.5C ) the amount of drug internalised per cell is greater than that of BNIPSpm. However, even with this increased in internalisation, no toxicity was observed. It is widely reported that the majority of nanoparticulate suspensions and colloids are internalised via endocytosis [40] . This mechanism of 'cellular drinking' is more rapid and the process of engulfing and membrane rearrangement results in greater cellular uptake of molecules compared to the diffusion mediated routes. Hence, greater internalisation is the likely reason for the decreased IC 50 of HNP-BNIPSpm (Fig. 5A ). The cellular uptake data shown in In order to gauge the effect of the novel formulation on the immune system, U937
human monocyte cells were differentiated in order to mimic macrophage like activity.
Interestingly, greater cellular uptake was observed with the free BNIPSpm compared to the HNP bound drug (Fig. 5B ). This result is quite surprising as monocyte cells typically 'eat' and 'destroy' any foreign bodies in the bloodstream. Perhaps the presence of the poly(ethylene glycol) mimics biological molecules and avoid being endocytosed by the cells. More likely however, is that fact that these are a noncancerous derived cell line and particularly after differentiation they are not proliferating rapidly and hence endocytosis may take longer. Hence, for U937 cells, drugs enter cells preferentially via the diffusion mediated pathways. This is reflected in the cytotoxicity data presented in Fig.5A where a significant increase in IC 50 was observed with HNP-BNIPSpm conjugation.
In order to determine whether reversal of drug binding resulted in toxicity enhancement in vitro, trypan blue cell viability counting was carried out after 24 h exposure to 50 µgmL -1 of the formulation. The protocol carried out was the same except these cells had been incubated at increased temperatures (44 ˚C, 60 ˚C) for 0.5
h. This exposure duration was deemed sufficient to initiate drug release (Fig. 4) without causing any adverse effect to the cells. Indeed, at increased temperatures the IC 50 values dropped although this was only found to be statistically significant (p<0.01) in the case of BxPC-3 cells exposed to 60 ˚C (Fig. 5C ). Although, this was only a crude experiment and it is not certain if it properly reflects the in vivo behavior of these drugs after heat initiated release.
Further investigation into the cellular state was studied after drug/formulation exposure using AFM imaging technique. The latter has often been used as an early indicator of in vitro fate since detailed cellular morphology can be observed. Figure   5D -E shows the topography images for all three cell lines undergoing the various treatment after 1 h exposure. Strikingly, the cancer cell lines incubated with HNPBNIPSpm (Fig.5D5, E5 ) showed completely different profiles to controls (Fig. 5D1,   E1 ) with total cellular rearrangement and breakdown starting to occur even after this short time exposure. In common with the cytotoxicity (Fig. 5A ) and uptake data ( Fig.   4B ), those cells treated with free drug (Fig.5D4, E4 ) also appeared unhealthy, but to a lesser extent. Unsurprisingly, the HNP (Fig.5D2, E2 ) or the gemcitabine treated cells (Fig.5D3, E3 ) did not look notably different to the control cells (Fig. 5D1, E1 ), with smooth, well defined and communicative surface. The U937 cells (Fig.5F ) followed a similar trend to their cytotoxicity and uptake data, whereby the cells treated with free drug (Fig.5 F4) looked less rounded and smooth compared to the control cells (Fig.   5F1 ). In agreement with the cytotoxicity data, those cells treated with HNP alone (Fig.5 F2) or gemcitabine (Fig.5 F3) did not look notably different from the control cells.
In vivo evaluation
The novel formulation (HNP-BNIPSpm) was tested on subcutaneous BxPC once per week over a 4-week period. In order to exploit the thermo-responsive properties of these formulations, laser irradiation was used. Extensive previous studies have been carried out in order to optimize the laser treatment duration in order to achieve temperatures that are likely to initiate drug release without adverse effects to tissue [34, 35] . Figure 6 A 1 shows a tumour excised from a control group mouse. Unfortunately, the mice from this group and the HNP alone group, did not complete the duration of the study. This is because their tumour volumes reached the maximum humane limit (0.9 cm 3 ) and hence the study had to be halted early. Looking at the tumour images (Fig.6 A) in conjunction with weight ( Fig.6 B) and volume ( Ideally, HNP-BNIPSpm without laser irradiation would not result in any tumour retardation for the clinical translation to occur. Hence, we postulate that surface modification using polymers to wrap the drugs onto the HNP surface until laser irradiation and subsequent release will improve their biocompatibility and reduce this observed toxicity. Work is underway in our laboratories in order to develop these second-generation systems.
Conclusion
This study realises the potential of HNPs as vehicles for heat triggered drug delivery in pancreatic cancer therapy. In general, loading capacity of drugs was affected by a number of factors including initial drug feeding concentration, the extent of cationic charge (number of amino groups in the drug backbone), the presence of sulfur in the drug and the type of interaction between drug and HNPs (electrostatic or covalent).
Our findings show that increasing the number of charges in the polyamine backbone leads to stronger electrostatic interaction with the gold surface of the HNP. BNIPSpm possessed favourable binding, which was reversible at 44°C. This means the drug could be released by heat stimulation via irradiation at the SPR in vivo. The possibility of using these systems clinically is not limited to the novel bisnaphthalimide compounds. Indeed, any charged drug molecule which exhibits desirable binding and uncoupling characteristics could be delivered by this route. Additionally, active transport mechanisms for precision targeting could be exploited using specific ligands.
Undoubtedly the surface chemistry is only limited by area and competition for binding sites. Exploitation of these systems for heat triggered drug delivery in combination with their imaging capability makes them suitable as theranostic agents.
The advantage of such systems is the ability to treat patients as soon as diagnosis is confirmed with more effective and targeting systems which results in reduction in the dosage required of these harsh cytotoxic agents in order to observe therapeutic effect, reduction in patient side effects and improved long-term outcome. In order for these systems to truly be classed as theranostics they must be completely biocompatible after drug conjugation until the point of laser initiated drug release. Hence, our lab are currently working on the next generation of these systems with careful attention to the surface chemistry and immunological response pushing this potential treatment further along the pipeline in order to create significant advancement in the treatment of pancreatic cancer which could be translated to other cancers. Figure 1. A 
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